Arcutis Biotherapeutics (ARQT) vs Organon (OGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Organon (OGN) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, gaining 92.9% versus a loss of 10.6%. Over five years, ARQT leads with a +58.1% price change compared with -55.4% for OGN. Organon is the larger company by market cap ($3.65 billion vs $3.33 billion), about 1.1 times the size, while Arcutis Biotherapeutics is growing revenue faster (+91.3% vs -2.9%).
On valuation, Organon trades at a lower forward P/E (3.8x vs 24.1x for Arcutis Biotherapeutics). Organon pays a dividend yielding 0.58%, while Arcutis Biotherapeutics does not currently pay one. Organon converts more of its revenue into profit, with a net margin of 3.0% versus -4.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | OGN |
|---|---|---|
| Share price | $26.36 | $13.89 |
| Market cap | $3.33B | $3.65B |
| 1-day change | -2.98% | -0.14% |
| YTD return | -9.23% | +93.72% |
| 1-year return | -10.61% | +92.92% |
| 5-year return | +58.13% | -55.38% |
| P/E ratio (TTM) | 119.82 | 17.81 |
| Forward P/E | 24.09 | 3.81 |
| EPS (TTM) | $0.22 | $0.78 |
| Dividend yield | 0.00% | 0.58% |
| Annual dividend | $0.00 | $0.08 |
| Revenue (latest FY) | $376.07M | $6.22B |
| Revenue growth (YoY) | +91.34% | -2.92% |
| Net income (latest FY) | $-16.14M | $187.00M |
| Gross margin | 90.24% | 53.30% |
| Operating margin | -3.25% | — |
| Net margin | -4.29% | 3.01% |
| 52-week high | $34.80 | $13.94 |
| 52-week low | $19.30 | $5.69 |
| Distance from 52-week high | -24.25% | -0.36% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +53.19% | -25.63% |
| Average volume | 2.58M | 2.74M |
| Shares outstanding | 126.46M | 262.62M |
| Employees | 354 | 10,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OGN has outperformed ARQT by 103.5 percentage points over the past year.
- Arcutis Biotherapeutics trades at a higher earnings multiple (119.8x vs 17.8x trailing P/E).
- Organon is more profitable, keeping 3.0 cents of every revenue dollar as net income versus -4.3 cents for Arcutis Biotherapeutics.
- Arcutis Biotherapeutics grew revenue faster in its latest fiscal year (+91.34% vs -2.92%).
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
ARQT vs OGN FAQ
Which is bigger, Arcutis Biotherapeutics or Organon?
Organon (OGN) is larger, with a market capitalization of $3.65B compared with $3.33B for Arcutis Biotherapeutics (ARQT).
Which stock has performed better over the past year, ARQT or OGN?
OGN returned +92.92% over the past 12 months, compared with -10.61% for ARQT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ARQT or OGN?
OGN has the lower trailing P/E at 17.8, versus 119.8 for ARQT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Arcutis Biotherapeutics or Organon?
Organon pays a dividend yielding 0.58%, while Arcutis Biotherapeutics does not currently pay a regular dividend.
Are Arcutis Biotherapeutics and Organon in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.